company background image
INLB

Item 9 Labs OTCPK:INLB Stock Report

Last Price

US$0.39

Market Cap

US$36.9m

7D

-3.1%

1Y

-77.1%

Updated

03 Oct, 2022

Data

Company Financials +
INLB fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

INLB Stock Overview

Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States.

Item 9 Labs Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Item 9 Labs
Historical stock prices
Current Share PriceUS$0.39
52 Week HighUS$2.00
52 Week LowUS$0.36
Beta0.43
1 Month Change-13.89%
3 Month Change-49.01%
1 Year Change-77.07%
3 Year Change-85.54%
5 Year Changen/a
Change since IPO-86.16%

Recent News & Updates

Shareholder Returns

INLBUS PharmaceuticalsUS Market
7D-3.1%-0.04%-2.5%
1Y-77.1%3.2%-23.2%

Return vs Industry: INLB underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: INLB underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is INLB's price volatile compared to industry and market?
INLB volatility
INLB Average Weekly Movement19.1%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: INLB is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: INLB's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a104Andrew Bowdenhttps://www.item9labscorp.com

Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona.

Item 9 Labs Fundamentals Summary

How do Item 9 Labs's earnings and revenue compare to its market cap?
INLB fundamental statistics
Market CapUS$36.89m
Earnings (TTM)-US$21.74m
Revenue (TTM)US$23.85m

1.5x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INLB income statement (TTM)
RevenueUS$23.85m
Cost of RevenueUS$15.88m
Gross ProfitUS$7.97m
Other ExpensesUS$29.71m
Earnings-US$21.74m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.23
Gross Margin33.41%
Net Profit Margin-91.15%
Debt/Equity Ratio37.3%

How did INLB perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is INLB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INLB?

Other financial metrics that can be useful for relative valuation.

INLB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.8x
Enterprise Value/EBITDA-5.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does INLB's PS Ratio compare to its peers?

INLB PS Ratio vs Peers
The above table shows the PS ratio for INLB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.8x
NTRB Nutriband
17.2x73.8%US$29.4m
RDHL RedHill Biopharma
0.4x22.8%US$29.6m
ELTP Elite Pharmaceuticals
1.1xn/aUS$35.5m
SHWZ Medicine Man Technologies
0.4x24.7%US$58.5m
INLB Item 9 Labs
1.5x21.2%US$36.9m

Price-To-Sales vs Peers: INLB is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (4.8x).


Price to Earnings Ratio vs Industry

How does INLB's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: INLB is good value based on its Price-To-Sales Ratio (1.5x) compared to the US Pharmaceuticals industry average (2.9x)


Price to Sales Ratio vs Fair Ratio

What is INLB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INLB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ratio4.7x

Price-To-Sales vs Fair Ratio: INLB is good value based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).


Share Price vs Fair Value

What is the Fair Price of INLB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate INLB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate INLB's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Item 9 Labs forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


41.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INLB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INLB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INLB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INLB's revenue (21.2% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: INLB's revenue (21.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if INLB's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Item 9 Labs performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-42.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: INLB is currently unprofitable.

Growing Profit Margin: INLB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: INLB is unprofitable, and losses have increased over the past 5 years at a rate of 42.1% per year.

Accelerating Growth: Unable to compare INLB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INLB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: INLB has a negative Return on Equity (-27.69%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Item 9 Labs's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: INLB's short term assets ($5.7M) do not cover its short term liabilities ($39.5M).

Long Term Liabilities: INLB's short term assets ($5.7M) exceed its long term liabilities ($2.6M).


Debt to Equity History and Analysis

Debt Level: INLB's net debt to equity ratio (36.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if INLB's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INLB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: INLB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23.9% each year


Discover healthy companies

Dividend

What is Item 9 Labs's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Item 9 Labs Dividend Yield vs Market
How does Item 9 Labs dividend yield compare to the market?
SegmentDividend Yield
Company (Item 9 Labs)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (Item 9 Labs)n/a

Notable Dividend: Unable to evaluate INLB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INLB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INLB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INLB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as INLB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Andrew Bowden (34 yo)

4.08yrs

Tenure

US$722,314

Compensation

Mr. Andrew Douglas Bowden is Chief Executive Officer of Item 9 Labs Corp. since November 18, 2019, Director since September 11, 2018 and serves as its President. Mr. Bowden has extensive experience with mu...


CEO Compensation Analysis

Andrew Bowden's Compensation vs Item 9 Labs Earnings
How has Andrew Bowden's remuneration changed compared to Item 9 Labs's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$22m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021n/an/a

-US$13m

Sep 30 2021US$722kUS$226k

-US$11m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020n/an/a

-US$11m

Sep 30 2020US$589kUS$169k

-US$12m

Jun 30 2020n/an/a

-US$13m

Mar 31 2020n/an/a

-US$12m

Dec 31 2019n/an/a

-US$11m

Sep 30 2019US$12kUS$12k

-US$10m

Compensation vs Market: Andrew's total compensation ($USD722.31K) is about average for companies of similar size in the US market ($USD781.86K).

Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: INLB's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: INLB's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of INLB?
Owner TypeNumber of SharesOwnership Percentage
VC/PE Firms4,884,0485.1%
Institutions5,000,0005.3%
Individual Insiders19,575,51420.6%
General Public65,753,04069.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.


Top Shareholders

Top 13 shareholders own 30.94% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.45%
Patrick Dugan
6,144,712$2.4m0%no data
5.46%
Andrew Poirier
5,198,045$2.0m0%no data
5.25%
Viridis Group I9 Capital Llc
5,000,000$1.9m0%no data
5.13%
Stockbridge Enterprises, L.P.
4,884,048$1.9m0%100%
5.03%
Mark Murro
4,788,623$1.9m0%no data
1.8%
Jeffrey Rassas
1,710,733$662.9k0%no data
1.05%
Michael Weinberger
998,885$387.1k0%no data
0.3%
Christopher Wolven
288,460$111.8k0%no data
0.22%
Andrew Bowden
205,000$79.4k0%no data
0.12%
Michael Keskey
117,647$45.6k0%no data
0.11%
Douglas Bowden
100,000$38.8k0%no data
0.022%
Eric Kutscher
20,906$8.1k0%no data
0.0026%
Ronald Miller
2,503$969.90%no data

Company Information

Item 9 Labs Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: Item 9 Labs Corp.
  • Ticker: INLB
  • Exchange: OTCPK
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$36.895m
  • Shares outstanding: 95.21m
  • Website: https://www.item9labscorp.com

Number of Employees


Location

  • Item 9 Labs Corp.
  • 2727 North 3rd Street
  • Suite 201
  • Phoenix
  • Arizona
  • 85004
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INLBOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2018

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Earnings2022/06/30
Annual Earnings2021/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.